Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

NEW YORK , May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

May 26, 2023

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

May 26, 2023

Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

NEW YORK , May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

May 23, 2023

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

Q1 2023 DANYELZA® record net product revenues of $20.3 million , driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 million for FY 2023

May 08, 2023

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

NEW YORK , April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023 , on Monday, May 8, 2023 , after the close of the U.S. financial markets.

Apr 28, 2023

Y-mAbs Announces Presentation of Naxitamab data at AACR

NEW YORK , April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Apr 18, 2023

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

NEW YORK , April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Apr 05, 2023

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

Q4 2022 DANYELZA® record net product revenues of $16.4 million , driving YoY growth of 71% and 31% sequential increase compared to Q3 2022 DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial guidance First ever SADA Phase I trial opened Cash and cash

Mar 30, 2023

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

NEW YORK , March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022 , on Thursday, March 30, 2023 , after the close of the U.S. financial markets.

Mar 21, 2023

Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

NEW YORK , Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced

Feb 02, 2023

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12